Sclerosing Cholangitis

Categories: Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Sclerosing Cholangitis

MalaCards integrated aliases for Sclerosing Cholangitis:

Name: Sclerosing Cholangitis 12 74 58 15 17
Primary Sclerosing Cholangitis 71
Cholangitis, Sclerosing 71
Fibrosing Cholangitis 12


Orphanet: 58  
Rare hepatic diseases

External Ids:

Disease Ontology 12 DOID:14268
MeSH 43 D015209
SNOMED-CT 67 235917005
ICD10 32 K83.09
UMLS via Orphanet 72 C0008313
Orphanet 58 ORPHA447771
UMLS 71 C0008313 C0566602

Summaries for Sclerosing Cholangitis

MalaCards based summary : Sclerosing Cholangitis, also known as primary sclerosing cholangitis, is related to sclerosing cholangitis, neonatal and cholangitis, primary sclerosing, and has symptoms including icterus An important gene associated with Sclerosing Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Allograft rejection and Bile secretion. The drugs Prednisone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and t cells, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 74 Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder... more...

Related Diseases for Sclerosing Cholangitis

Diseases in the Sclerosing Cholangitis family:

Cholangitis, Primary Sclerosing Secondary Sclerosing Cholangitis

Diseases related to Sclerosing Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 676)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 35.3 DCDC2 CLDN1
2 cholangitis, primary sclerosing 32.3 TNF NR1I2 NR1H4 NOD2 MIR222 MADCAM1
3 liver cirrhosis 32.1 HP HLA-DRB1 GPT GGT1 ALB
4 pancreatitis 32.0 TNF GGT1 CFTR ALB
5 colitis 32.0 TNF NOD2 MADCAM1 HLA-DRB1
6 autoimmune pancreatitis 31.8 TNF HLA-DRB1 CFTR CD40LG ALB
7 cholecystitis 31.8 HP GPT ALB
8 autoimmune hepatitis 31.7 TNF HLA-DRB1 GPT GGT1 CD40LG ALB
9 obstructive jaundice 31.7 TNF GPT GPBAR1 GGT1 ALB
10 crohn's disease 31.5 TNF NOD2 MADCAM1 HP HLA-DRB1 ALB
11 esophageal varix 31.5 GPT GGT1 ALB
12 ascending cholangitis 31.5 GPT ALB
13 acute cholangitis 31.5 GPT GGT1 ALB
14 choledocholithiasis 31.5 GPT GGT1 ALB ABCB4
15 ileitis 31.4 TNF NOD2 MADCAM1
16 portal hypertension 31.4 TNF NR1H4 GPT CFTR CD40LG ALB
17 liver disease 31.4 TNF NR1H4 GPT GGT1 ALB ABCB4
18 acute pancreatitis 31.3 TNF GPT CFTR ALB
19 pericholangitis 31.2 ABCB4 ABCB11
20 acalculous cholecystitis 31.2 GPT CD40LG ALB
21 hepatitis a 31.2 TNF GPT GGT1 ALB
22 hepatic encephalopathy 31.1 TNF GPT ALB
23 sarcoidosis 1 31.1 TNF NOD2 HLA-DRB1 CD40LG
24 graft-versus-host disease 31.1 TNF HLA-DRB1 HLA-B
25 cholestasis 31.1 TNF NR1I2 NR1H4 GPT GPBAR1 GGT1
26 bile duct cysts 31.1 GPT GGT1 ABCB4
27 pyoderma 31.0 TNF NOD2 CD40LG
28 diarrhea 31.0 TNF NOD2 GPT CFTR CD40LG ALB
29 spondylitis 31.0 TNF NOD2 HLA-B
30 acute kidney failure 31.0 HP GPT ALB
31 suppurative cholangitis 31.0 GPT GGT1 ABCB4
32 deficiency anemia 31.0 TNF HP GGT1 ALB
33 echinococcosis 30.9 TNF HLA-DRB1 HLA-B CD40LG
34 acquired immunodeficiency syndrome 30.9 TNF MADCAM1 HLA-B CD40LG ALB
35 intestinal disease 30.9 TNF NOD2 MIR222 ALB
36 inflammatory bowel disease 30.9 TNF NR1I2 NR1H4 NOD2 MADCAM1 HP
37 fatty liver disease 30.9 TNF NR1H4 GPT GGT1 ALB
38 autoimmune hepatitis type 1 30.9 HLA-DRB1 GPT
39 viral hepatitis 30.9 TNF HLA-DRB1 GPT GGT1 CD40LG ALB
40 hepatitis c 30.8 TNF GPT GGT1 CLDN1
41 alpha-1-antitrypsin deficiency 30.8 TNF GPT CFTR ALB
42 microscopic polyangiitis 30.8 TNF HLA-DRB1
43 spondyloarthropathy 1 30.8 TNF NOD2 HLA-B CD40LG
44 red cell aplasia 30.8 HLA-DRB1 HLA-B ALB
45 alcoholic liver cirrhosis 30.8 TNF GPT ALB
46 non-alcoholic steatohepatitis 30.8 TNF NR1H4 GPT GGT1 ALB
47 hemochromatosis, type 1 30.7 HP HLA-B GPT CFTR
48 neutropenia 30.7 TNF GPT CD40LG ALB
49 bacterial infectious disease 30.7 TNF NOD2 CFTR CD40LG
50 thrombophlebitis 30.7 TNF CD40LG ALB

Graphical network of the top 20 diseases related to Sclerosing Cholangitis:

Diseases related to Sclerosing Cholangitis

Symptoms & Phenotypes for Sclerosing Cholangitis

UMLS symptoms related to Sclerosing Cholangitis:


MGI Mouse Phenotypes related to Sclerosing Cholangitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ABCB11 ABCB4 ALB CD40LG CFTR CLDN1
2 immune system MP:0005387 9.7 ABCB4 ALB CD40LG CFTR FUT2 GGT1
3 liver/biliary system MP:0005370 9.28 ABCB11 ABCB4 ALB CFTR GPBAR1 HP

Drugs & Therapeutics for Sclerosing Cholangitis

Drugs for Sclerosing Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Ofloxacin Approved Phase 4 82419-36-1 4583
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12 Immunosuppressive Agents Phase 4
13 Immunologic Factors Phase 4
14 Anti-Inflammatory Agents Phase 4
15 Hormones Phase 4
16 Hormone Antagonists Phase 4
17 glucocorticoids Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Methylprednisolone Acetate Phase 4
20 Anti-Bacterial Agents Phase 4
21 Antibiotics, Antitubercular Phase 4
22 Cytochrome P-450 Enzyme Inhibitors Phase 4
Vancomycin Approved Phase 2, Phase 3 1404-90-6 14969 441141
Ursodeoxycholic acid Approved, Investigational Phase 3 128-13-2 31401
Simvastatin Approved Phase 3 79902-63-9 54454
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
27 Hypolipidemic Agents Phase 3
28 Lipid Regulating Agents Phase 3
29 Anticholesteremic Agents Phase 3
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
31 Clofibric Acid Phase 3 882-09-7
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
Curcumin Approved, Experimental, Investigational Phase 1, Phase 2 458-37-7 969516
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
Sulfasalazine Approved Phase 2 599-79-1 5353980 5359476
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
Fenofibrate Approved Phase 1, Phase 2 49562-28-9 3339
Fluorouracil Approved Phase 2 51-21-8 3385
Pancrelipase Approved, Investigational Phase 2 53608-75-6
Gemcitabine Approved Phase 2 95058-81-4 60750
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
45 Alkylating Agents Phase 2
46 Mitomycins Phase 2
47 2-chloro-3'-deoxyadenosine Phase 2
48 Anti-HIV Agents Phase 2
49 Anti-Retroviral Agents Phase 2
50 TAK-652 Phase 2

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
3 A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease Completed NCT02703194 Phase 4 Prednisone;Leflunomide
4 Randomized Trial of Short Antibiotic Course to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
5 Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
6 Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial Unknown status NCT00161148 Phase 3 Probiotics
7 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
8 Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
9 Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed NCT01802073 Phase 3 Oral Vancomycin
10 Diagnosis of Intraepithelial Neoplasia in Patients With Long Standing Ulcerative Colitis With Chromoscopic Guided Endomicroscopy Completed NCT00352404 Phase 3
11 Digital SpyGlass Cholangioscopy Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
12 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis Recruiting NCT03890120 Phase 3 Cilofexor;Placebo
13 Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing norUrsodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Recruiting NCT03872921 Phase 3 norUrsodeoxycholic Acid
14 A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing Cholangitis Recruiting NCT03710122 Phase 2, Phase 3 Vancomycin
15 Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study Not yet recruiting NCT04133792 Phase 3 Simvastatin 40mg;Placebo oral tablet
16 Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy Not yet recruiting NCT04309773 Phase 3 Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy;Placebo of Bezafibrate in addition to standard UDCA therapy
17 A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
18 Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis Unknown status NCT01688024 Phase 2 Mitomycin C;Normal saline
19 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine
20 A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
21 A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
22 A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis Completed NCT02943460 Phase 2 Cilofexor;Placebo to match Cilofexor
23 PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
24 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
25 An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Completed NCT02978339 Phase 1, Phase 2 Curcumin
26 Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
27 A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC). Completed NCT02239211 Phase 2 BTT1023
28 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis Completed NCT02177136 Phase 2 OCA;Placebo
29 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Completed NCT02424175 Phase 1, Phase 2
30 A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis Completed NCT00583076 Phase 2 AST-120
31 Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial Completed NCT01584388 Phase 1, Phase 2 Rituximab
32 Investigation of the Activity of Vidofludimus Calcium, a Novel, Orally Available, Small Molecule Inhibitor of Dihydroorotate Dehydrogenase, as a Treatment for Primary Sclerosing Cholangitis (PSC) Recruiting NCT03722576 Phase 2 Vidofludimus calcium
33 A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC) Recruiting NCT03561584 Phase 2 Sulfasalazine;Placebo
34 An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis Recruiting NCT03359174 Phase 2 All-trans retinoic acid
35 An Adaptive,Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis Recruiting NCT02997878 Phase 1, Phase 2
36 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Recruiting NCT01988506 Phase 2 Interleukin 2
37 A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Active, not recruiting NCT03333928 Phase 2 HTD1801;Placebo
38 Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis Active, not recruiting NCT03516006 Phase 1, Phase 2 UCMSC;UDCA
39 A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC) Not yet recruiting NCT03678480 Phase 2 HTD1801;Ursodeoxycholic Acid
40 A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC) Suspended NCT04024813 Phase 2 Seladelpar;Placebo to match Seladelpar
41 Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis Terminated NCT01142323 Phase 1, Phase 2 fenofibrate
42 A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) Terminated NCT03394781 Phase 2 DUR-928
43 Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis Terminated NCT00953615 Phase 2 Thalidomide
44 Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma Terminated NCT00983541 Phase 2 Fluorouracil (5-FU);Gemcitabine
45 A Pilot Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis Withdrawn NCT02780752 Phase 1, Phase 2 hymecromone
46 Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis Withdrawn NCT00588458 Phase 2
47 Phase 1 Study of Intrahepatic Reinfusion of Highly Purified CD133+ Stem Cells in Patients With End-Stage Liver Disease Unknown status NCT01025622 Phase 1
48 Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC) Completed NCT00630942 Phase 1 Minocycline
49 A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis Completed NCT01695174 Phase 1 Xifaxan
50 A First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy Subjects Completed NCT03099603 Phase 1 HTD1801

Search NIH Clinical Center for Sclerosing Cholangitis

Genetic Tests for Sclerosing Cholangitis

Anatomical Context for Sclerosing Cholangitis

MalaCards organs/tissues related to Sclerosing Cholangitis:

Liver, Colon, T Cells, Testes, Neutrophil, Skin, Eye

Publications for Sclerosing Cholangitis

Articles related to Sclerosing Cholangitis:

(show top 50) (show all 6130)
# Title Authors PMID Year
Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. 61
32130494 2020
Living Donor Liver Transplantation for Perihilar Cholangiocarcinoma: Outcomes and Complications. 61
32035181 2020
Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient. 61
32284868 2020
Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017. 61
32412143 2020
Genetic variants of UDP-glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis. 61
32378294 2020
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. 61
32165251 2020
Comparison of Coagulation Conditions in Patients With Liver Cirrhosis Due to Primary Sclerosing Cholangitis and Nonbiliary Causes of Cirrhosis Before Orthotopic Liver Transplant. 61
32552627 2020
Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. 61
31493578 2020
Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to Ursodiol. 61
32480421 2020
Extrahepatic biliary duplication with heterotopic gastric mucosa in a 46,XX male patient. 61
32179063 2020
CTLA-4 Expression Plays a Role in PSC and PBC Progression. 61
32545568 2020
A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. 61
32529198 2020
Blockade of BAFF Reshapes the Hepatic B Cell Receptor Repertoire and Attenuates Autoantibody Production in Cholestatic Liver Disease. 61
32332110 2020
In Vivo 1 H MR Spectroscopy of Biliary Components of Human Gallbladder at 7T. 61
32501627 2020
Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance. 61
31446183 2020
Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis. 61
32526342 2020
Use of Butorphanol as Treatment for Cholestatic Itch. 61
32556969 2020
Senescent Cholangiocytes Release Extracellular Vesicles that Alter Target Cell Phenotype Via the Epidermal Growth Factor Receptor. 61
32558183 2020
A rare presentation of hepatolithiasis in an adolescent patient: A case report. 61
32563817 2020
Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. 61
32546343 2020
Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling. 61
32054995 2020
Greater Peripouch Fat Area on CT Image Is Associated with Chronic Pouchitis and Pouch Failure in Inflammatory Bowel Diseases Patients. 61
32500285 2020
Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. 61
32222826 2020
The role of complement activation in autoimmune liver disease. 61
32234403 2020
Patient and clinician opinions of patient reported outcome measures (PROMs) in the management of patients with rare diseases: a qualitative study. 61
32522194 2020
Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. 61
32531342 2020
Hematopoietic stem cell transplantation in CD40 ligand deficiency: A single-center experience. 61
32573870 2020
Novel CLDN1 Deletion Associated with Ichthyosis, Sclerosing Cholangitis and Acquired Alopecia. 61
32424433 2020
[Surgical treatment of primary sclerosing cholangitis : Experiences from 30 years in a single center cohort with 173 consecutive patients]. 61
32488382 2020
Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. 61
31683058 2020
Great Expectations: Can Magnetic Resonance Elastography Accelerate Progress in Primary Sclerosing Cholangitis Research? 61
31863860 2020
Immunoglobulin G subtypes-1 and 2 differentiate immunoglobulin G4-associated sclerosing cholangitis from primary sclerosing cholangitis. 61
32349627 2020
Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study. 61
32012415 2020
Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). 61
32505896 2020
Liver Elastography in Primary Sclerosing Cholangitis Patients Using Three Different Scanner Systems. 61
32507342 2020
Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. 61
32250997 2020
Gut microbiome in primary sclerosing cholangitis: A review. 61
32550753 2020
Comorbidities in adolescents with inflammatory bowel disease: findings from a population-based cohort study. 61
31801156 2020
Langerhans cell histiocytosis confined to extrahepatic bile duct causing sclerosing cholangitis in child: a case report. 61
32548778 2020
Refractory Inflammatory Bowel Disease Associated With Sclerosing Cholangitis, Diabetes Insipidus, and Myeloid Neoplasm: Langerhans Cell Histiocytosis Was Hiding Since the Beginning. 61
32530029 2020
The clinical characteristics, pre- and post-liver transplantation outcomes in patients having autoimmune overlap syndromes. 61
32073690 2020
Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Diseases, Based on Sex, Race, and Age. 61
32445859 2020
Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. 61
32414025 2020
Alemiroation of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment. 61
32142732 2020
Protein Abundance of Hepatic Drug Transporters in Patients With Different Forms of Liver Damage. 61
31697849 2020
The management of gallbladder polyps. 61
32473822 2020
[Recent Updates of Immunoglobulin G4-related Pancreatobiliary Disease]. 61
32448857 2020
Roles of trained immunity in the pathogenesis of cholangiopathies: a novel therapeutic target. 61
32463941 2020
The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) index: a prognostic tool for children. 61
32464706 2020
Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. 61
31665288 2020

Variations for Sclerosing Cholangitis

Expression for Sclerosing Cholangitis

Search GEO for disease gene expression data for Sclerosing Cholangitis.

Pathways for Sclerosing Cholangitis

GO Terms for Sclerosing Cholangitis

Cellular components related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.92 TNF MIR222 HP HLA-DRB1 GPT GGT1
2 extracellular exosome GO:0070062 9.81 HP HLA-DRB1 HLA-B GPT GGT1 FUT2
3 cell surface GO:0009986 9.43 TNF NOD2 HLA-DRB1 HLA-B CFTR CD40LG
4 intercellular canaliculus GO:0046581 9.26 ABCB4 ABCB11
5 integral component of plasma membrane GO:0005887 9.23 TNF HLA-DRB1 HLA-B CLDN1 CFTR CD40LG

Biological processes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 TNF MADCAM1 HLA-DRB1 HLA-B CD40LG
2 defense response to bacterium GO:0042742 9.78 TNF NR1H4 NOD2 HP
3 cellular response to lipopolysaccharide GO:0071222 9.73 TNF NR1I2 NR1H4 NOD2
4 regulation of inflammatory response GO:0050727 9.67 TNF NOD2 GGT1
5 defense response GO:0006952 9.62 TNF NOD2 HP HLA-B
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 TNF NOD2 MIR222 HLA-DRB1 GPBAR1
7 lipid homeostasis GO:0055088 9.54 NR1I2 NR1H4 ABCB4
8 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.43 NR1H4 HLA-DRB1 CFTR
9 regulation of immunoglobulin secretion GO:0051023 9.4 TNF CD40LG
10 detection of bacterium GO:0016045 9.13 NOD2 HLA-DRB1 HLA-B
11 cellular response to bile acid GO:1903413 8.8 NR1H4 GPBAR1 ABCB4

Molecular functions related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.13 CFTR ABCB4 ABCB11
2 bile acid receptor activity GO:0038181 8.62 NR1H4 GPBAR1

Sources for Sclerosing Cholangitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....